Bukwang Pharmaceutical is accelerating its new drug development efforts by submitting an Investigational New Drug (IND) application to advance its subsidiary Contera Pharma’s Parkinson’s disease treatment candidate CP-012 into a global Phase 2 clinical trial. After laying the groundwork for a turnaround through a global co-research deal and improved earnings last year, key focus areas in the second half include clinical progress, expansion of RNA-based technologies, and strengthening manufacturing competitiveness.
According to industry sources on the 1st, Bukwang Pharmaceutical recently filed an IND application for CP-012’s global Phase 2 trial. CP-012 is being developed by Contera Pharma as a treatment for morning akinesia in Parkinson’s disease patients. In a Phase 1b study, the candidate demonstrated feasibility in formulation and was found to be well tolerated.
The company plans to proceed to a global Phase 2 study upon IND approval. If early efficacy signals are confirmed, expectations are rising for potential co-development or technology transfer agreements with global pharmaceutical companies.
Last year, Contera Pharma signed a RNA-based co-research agreement with Danish pharmaceutical company Lundbeck, receiving industry validation of its technology capabilities. The deal structure includes upfront payments, research funding, milestone-based payments across development stages, and sales royalties.
The agreement is viewed as a key validation of its RNA technology in the global market. Industry observers say this year could be a pivotal point when progress in CP-012’s clinical development and RNA technology advancement begins to be reflected more directly in the company’s valuation.
The global pharmaceutical and biotech industry is increasingly focused on platform technologies that can expand across multiple indications, rather than single drug candidates.
RNA therapeutics are also expanding beyond rare diseases into central nervous system (CNS) disorders, oncology, and metabolic diseases, positioning themselves as a next-generation treatment modality. Advances in delivery systems and chemical modification technologies are improving commercialization prospects, making the field one of strong long-term growth potential.
Contera Pharma is accelerating efforts to enhance its RNA technology in line with these trends. Additional global partnerships could further strengthen its long-term growth engine.
Bukwang’s core business competitiveness is also improving. Last year, steady growth in key products such as diabetic neuropathy treatments Dexid and Thiocid supported stable performance, while CNS drug Latuda contributed to earnings improvement through expanded prescriptions.
The stable growth of flagship products is providing a steady cash flow base, supporting continued investment in new drug development and expansion initiatives.
Strengthening manufacturing competitiveness is another key priority. Bukwang recently completed its acquisition of Korea Union Pharmaceutical and is integrating its production systems. The company plans to gradually transfer outsourced production items in-house and improve utilization of its manufacturing facilities to enhance cost efficiency. Once fully implemented, the expanded production base is expected to have a positive impact on profitability.
In the short term, however, earnings may be weighed down by base effects from upfront payments related to last year’s Lundbeck collaboration, increased R&D investment, and costs associated with the stabilization of Korea Union Pharmaceutical. Nonetheless, continued growth in core products and the consolidation benefits from the acquisition are expected to maintain an overall upward trajectory in revenue.